Revised Intimation of Schedule of Investors/Analysts call to be held on Friday, May 15, 2026, 15.00 IST to discuss the Company''s audited financial results for the quarter and year ended ....
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences has filed a revised intimation with BSE and NSE about a change in the panel for their scheduled investor/analyst conference call on May 15, 2026, at 3:00 PM IST. One management panel member is unable to attend due to an unavoidable scheduling conflict, but the remaining panel members including MD & CEO Sandeep Rao and CFO Sarat Kumar will participate as scheduled. The call is to discuss the company's audited financial results for Q4 and full year ended March 31, 2026. All other details of the conference call remain unchanged. The company has issued this notification for transparency and compliance with SEBI (LODR) Regulations, 2015.
This is a minor, procedural update with negligible impact on shareholders. The conference call will proceed as scheduled to discuss Q4FY26 financial results with key management still participating. No material changes to business operations or financial outlook are indicated.